Publication

Handgrip Strength Seems Not to Be Affected by COPD Disease Progression: A Longitudinal Cohort Study

Journal Paper/Review - Feb 19, 2020

Units
PubMed
Doi

Citation
Kohlbrenner D, Kohler M, Brack T, Brutsche M, Frey M, Irani S, Leuppi J, Thurnheer R, Roeder M, Sievi N, Clarenbach C. Handgrip Strength Seems Not to Be Affected by COPD Disease Progression: A Longitudinal Cohort Study. COPD 2020; 17:150-155.
Type
Journal Paper/Review (English)
Journal
COPD 2020; 17
Publication Date
Feb 19, 2020
Issn Electronic
1541-2563
Pages
150-155
Brief description/objective

Skeletal muscle dysfunction, functional exercise capacity impairment and reduced physical activity are characteristic features in patients with chronic obstructive pulmonary disease (COPD). Assessments addressing muscle strength of the upper limb, such as measurement of handgrip strength (HGS), are rarely performed and reported. We aimed to analyze the course of HGS and possible predictors of changes in HGS over time in COPD. Yearly assessments of various disease markers were performed for a follow-up of up to seven years in a cohort of COPD patients to assess the longitudinal disease process. Data of 194 patients with at least one follow-up measurement were analyzed. HGS decreased significantly by = -0.86 (95% CI -1.09/-0.62,  < 0.001) over time. The multivariate mixed effects model showed an independent association between greater annual declines in HGS and lower numbers of steps per day by  = 0.11 (95% CI 0.03/0.18,  = 0.006) and an enhanced change in COPD Assessment Test scores by = -0.01 (95% CI -0.01/-0.00,  = 0.034). No evidence for an independent association between annual decline in HGS and FEV% pred. by = -0.01 (95% CI -0.03/0.01,  = 0.297) was shown. Patients who died during follow-up did not exhibit greater declines in HGS compared to survivors ( = 0.884). Although HGS significantly decreased over time, no pathophysiological link with COPD disease progression could be demonstrated. Previous cross-sectional associations between HGS and mortality could not be confirmed in this longitudinal setting. Our data suggests that repeated monitoring of HGS in clinical settings seems not to be helpful to predict COPD specific disease progression.